Beta
180697

Could Allicin Inhalation Bring Covid-19 Pandemic Under Control: New delivery of ancient medicine garlic

Article

Last updated: 22 Jan 2023

Subjects

-

Tags

Medicine

Abstract

Urgent researches are needed to test potential therapeutic agents against COVID-19 pandemic. Several studies are evaluating the beneficial and harmful effects of different pharmacological interventions such as antimalarial drugs, antiviral drugs, biologics, and interferon. To the best of our knowledge there was no trial for inhalation of raw freshly crushed garlic as a COVID-19 therapeutic although of many beneficial effects with minimal side effects. When the bulbs of garlic are cutted or crushed alliin is transformed into the Allicin by the enzyme alliinase. Allicin has anti-viral, anti-IL-6, anti-platelets and immunomodulatory effect; properties that could help to alleviate SARS-CoV-2 rapid spread, infection and subsequent complications.
Allicin may be one of our best choices in the current Covid-19 pandemic because of its direct and indirect anti-viral activities with minimal side effects. Virucidal activity can reduce infection load, prevent infection and or may be of a value for significant treatment.
Keywords: COVID-19; SARS-CoV-2; pandemic; garlic; Allicin; inhalation

DOI

10.21608/jmr.2021.74678.1065

Keywords

Keywords: COVID-1, pandemic, Garlic, Allicin, inhalation

Authors

First Name

Samah

Last Name

Abozaid

MiddleName

-

Affiliation

anatomy - medical college of ElMinia university

Email

samah.abuzaid@ucm.edu.sa

City

-

Orcid

-

Volume

3

Article Issue

2

Related Issue

26070

Issue Date

2021-07-01

Receive Date

2021-04-30

Publish Date

2021-07-01

Page Start

89

Page End

94

Online ISSN

2636-3909

Link

https://jmr.journals.ekb.eg/article_180697.html

Detail API

https://jmr.journals.ekb.eg/service?article_code=180697

Order

6

Type

Reviews

Type Code

779

Publication Type

Journal

Publication Title

Journal of Modern Research

Publication Link

https://jmr.journals.ekb.eg/

MainTitle

-

Details

Type

Article

Created At

22 Jan 2023